Background
Following the scale-up of intervention efforts, malaria burden has decreased dramatically in Solomon Islands (SI). Submicroscopic and asymptomatic
Plasmodium vivax
infections are now the major challenge for malaria elimination in this country. Since children have higher risk of contracting malaria, this study investigated the dynamics of
Plasmodium
spp. infections among children including the associated risk factors of residual
P. vivax
burden.
Methods
An observational cohort study was conducted among 860 children aged 0.5–12 years in Ngella (Central Islands Province, SI). Children were monitored by active and passive surveillances for
Plasmodium
spp. infections and illness. Parasites were detected by quantitative real-time PCR (qPCR) and genotyped. Comprehensive statistical analyses of
P. vivax
infection prevalence, molecular force of blood stage infection (
mol
FOB) and infection density were conducted.
Results
Plasmodium vivax
infections were common (overall prevalence: 11.9%), whereas
Plasmodium falciparum
infections were rare (0.3%) but persistent. Although children acquire an average of 1.1 genetically distinct
P. vivax
blood-stage infections per year, there was significant geographic heterogeneity in the risks of
P. vivax
infections across Ngella (prevalence: 1.2–47.4%, p < 0.01;
mol
FOB: 0.05–4.6/year, p < 0.01). Malaria incidence was low (IR: 0.05 episodes/year-at-risk). Age and measures of high exposure were the key risk factors for
P. vivax
infections and disease. Malaria incidence and infection density decreased with age, indicating significant acquisition of immunity. G6PD deficient children (10.8%) that did not receive primaquine treatment had a significantly higher prevalence (
a
OR: 1.77, p = 0.01) and increased risk of acquiring new bloodstage infections (
mol
FOB
a
IRR: 1.51, p = 0.03), underscoring the importance of anti-relapse treatment.
Conclusion
Residual malaria transmission in Ngella exhibits strong heterogeneity and is characterized by a high proportion of submicroscopic and asymptomatic
P. vivax
infections, alongside sporadic
P. falciparum
infections. Implementing an appropriate primaquine treatment policy to prevent
P. vivax
relapses and specific targeting of control interventions to high risk areas will be required to accelerate ongoing control and elimination activities.
Electronic supplementary material
The online version of this article (10.1186/s12936-019-2727-9) contains su...